Table 1.
Demographic and clinical characteristics in patients with multiple myeloma with at least one rapid infusion during their first daratumumab-containing treatment regimen
| Characteristics | N=147 |
|---|---|
| Demographic characteristicsa | |
| Age (years), mean ± SD [median, IQR] | 71.9 ± 9.0 [73.0; 13.0] |
| Female sex, n (%) | 66 (44.9) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 8 (5.4) |
| Not Hispanic or Latino | 131 (89.1) |
| Unknown | 8 (5.4) |
| Year of index dateb, n (%) | |
| 2015 | 0 (0.0) |
| 2016 | 15 (10.2) |
| 2017 | 70 (47.6) |
| 2018 | 61 (41.5) |
| 2019 | 1 (0.7) |
| Clinical characteristics | |
| Time between initial MM diagnosis and index date (years), mean ± SD [median, IQR] | 3.4 ± 4.3 [2.5; 3.4] |
| MM stagec, n (%) | |
| ISS Stage I | 11 (7.5) |
| ISS Stage II | 20 (13.6) |
| ISS Stage III | 46 (31.3) |
| Unknown | 70 (47.6) |
| ECOG performance statusa, n (%) | |
| 0 | 39 (26.5) |
| 1 | 82 (55.8) |
| 2 | 15 (10.2) |
| 3 | 3 (2.0) |
| Unknown | 8 (5.4) |
| Number of prior antineoplastic treatment regimensd, mean ± SD [median, IQR] | 2.5 ± 2.1 [2; 3] |
| One or more prior treatment regimen | 128 (87.1) |
| No prior treatment regimen | 19 (12.9) |
Data are presented as mean ± standard deviation [median; interquartile range] or N (%) unless otherwise indicated
ECOG Eastern Cooperative Oncology Group, ISS International Staging System, MM multiple myeloma
aMeasured on the index date
bThe study period ranged from 16 November 2015 to 15 March 2019
cMeasured prior to or on the index date
dAnytime prior to the index date